Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
By Amina Niasse NEW YORK, Aug 12 (Reuters) - Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's
Hims & Hers Health raised its 2026 revenue outlook to between $3.1 billion and $3.3 billion from its earlier guidance between $2.8 billion and $3 billion.
Hims & Hers raises its 2026 revenue outlook as AI boosts engagement, specialty care expands and Eucalyptus extends its international reach despite margin pressure.
Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here’s what to expect.
Aug 11 (Reuters) - Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast. The company posted second-quarter revenue on Monday that topped expectations and added more than 300,000 subscribers.
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally. Chief Financial Officer Yemi Okupe said dome
The telehealth platform said it now projects $3.1 billion to $3.3 billion in revenue for the year, up from a previous target for $2.8 billion to $3 billion.
NEW YORK, Aug 10 (Reuters) - Hims & Hers Health on Monday posted second-quarter revenue above estimates and raised its annual revenue forecast, as the telehealth company benefited from an increase in
This week, we pivot to "Inflation Week," with Wednesday and Thursday morning bringing new monthly price index data.
Monday Earnings (a.m): Barrick Mining Earnings (p.m.): Simon Property, Rocket Lab, JBS, Hims & Hers Health, Trump Media Tuesday Economic data: NFIB small-business index for July, existing home sales Earnings: Cardinal Health, Lumentum, CoreWeave, Super Micro, On Holding, Smithfield Foods Wednesday Inflation data: Consumer price index for July, 8:30 a.
SharkNinja (NYSE:SN) reported second-quarter 2026 results marked by accelerating sales growth, higher adjusted earnings and a raised full-year outlook, as the company cited broad demand across domestic and international markets, product categories and sales channels. Net sales increased 22.2% year
Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr
Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures. Chief Executive Officer Andrew Toy said the company views its Clove
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.
According to the suit, Hims & Hers shared lists of certain customers, and the actions of visitors on its website, with advertisers such as Meta and Snap, even though it claimed its service maintains consumers’ privacy.
The U.S. Federal Trade Commission on Wednesday sued the telehealth company over allegations it shared sensitive user health data with advertisers.
Federal Trade Commission is suing Hims & Hers alleging the telehealth platform shared users' health data with online advertisers despite promising privacy and engaged in deceptive billing and cancellation practices, an FTC spokesperson said. Hims & Hers is one of the largest telehealth players in the market for weight loss drugs.
The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared users' health data with online advertisers, despite promising privacy, and engaged in deceptive billing and cancellation practices. Hims & Hers stock added to losses after the news and was trading down around 12%. The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which it ships straight to customers.
Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them. FDA Panel Splits,...
A cash-secured put on Hims & Hers stock is one way to potentially buy the stock for a discount or achieve a healthy return.
The deal adds telehealth operations in Australia, Canada and Japan.
Agilent Technologies (NYSE:A) raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system. CEO Padraig McDonnell
Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy...
By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's
June S&P 500 E-Mini futures (ESM26) are up +0.25%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.79% this morning, buoyed by gains in technology stocks, while investors gear up for crucial U.S. producer inflation data and the highly anticipated Trump-Xi summit.
Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after the bell. Here’s what to expect.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
